Capital Research Global Investors Bridge Bio Pharma, Inc. Transaction History
Capital Research Global Investors
- $479 Billion
- Q2 2025
A detailed history of Capital Research Global Investors transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 3,988,298 shares of BBIO stock, worth $205 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,988,298
Previous 4,667,402
14.55%
Holding current value
$205 Million
Previous $161 Million
6.73%
% of portfolio
0.04%
Previous 0.04%
Shares
6 transactions
Others Institutions Holding BBIO
# of Institutions
408Shares Held
188MCall Options Held
11.3MPut Options Held
2.2M-
Viking Global Investors LP18.6MShares$955 Million2.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.5MShares$848 Million0.01% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY13.3MShares$683 Million22.63% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$641 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X09.28MShares$477 Million0.21% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $7.63B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...